Advertisement
A or AZTA or RVTY
Which Stock Would AI Choose? Agilent Technologies (A) vs. Azenta (AZTA) vs. Revvity (RVTY) Stock Comparison
Key Takeaways
- A benefits from FDA approvals in diagnostics like PD-L1 assays, supporting steady performance in life sciences instrumentation amid recent market recovery.
- AZTA faces headwinds from Q2 earnings miss, impairments in Multiomics and Sample Management, and lowered FY26 guidance, leading to sharp share price declines.
- RVTY delivered Q1 revenue and EPS beats with 7% growth, bolstered by plans to divest China immunodiagnostics for enhanced margins, driving recent gains.
- All three operate in life sciences and diagnostics, but A and RVTY show stronger recent momentum versus AZTA's execution challenges.
- Market caps differ significantly: A at $33B, RVTY at $11B, AZTA at $859M, influencing relative volatility and risk profiles.
- Tickeron AI signals favor upward trends for A and RVTY via moving average crossovers and MACD positives.
Introduction
This stock comparison examines A, AZTA, and RVTY, all key players in the life sciences and diagnostics sectors providing instruments, services, and solutions for research, drug development, and clinical applications. Traders seeking exposure to biotech tools and investors tracking healthcare innovation will find value in their relative performance amid recent earnings cycles and sector shifts. With broader market volatility in diagnostics and sample management, this analysis highlights price behaviors, sentiment drivers, and positioning in recent market activity.
A Overview and Recent Performance
Agilent Technologies (A), a leader in life sciences, diagnostics, and applied chemical markets, offers instruments like chromatography and mass spectrometry systems, alongside services via its CrossLab segment. In recent weeks, shares traded around $117, within a 52-week range of $104.79-$160.27, reflecting YTD gains of 13%. Key influences include FDA approval for its PD-L1 IHC 22C3 pharmDx assay, enhancing precision oncology tools, and leadership changes like appointing Michael Buckner as Chief Legal Officer. Analyst targets average $160, signaling undervaluation (P/E 26), though price target trims reflect execution caution. Sentiment has stabilized with moving average crossovers indicating upward momentum.
AZTA Overview and Recent Performance
Azenta (AZTA) specializes in sample management solutions, including automated storage and cryogenic systems, plus multiomics services like gene sequencing. Shares recently plunged over 24% to around $18.66 following Q2 FY26 results showing $145M revenue (down 3% organically), adjusted EBITDA margin of 5.4%, and non-GAAP EPS loss of $0.04, missing expectations due to North American demand softness and impairments totaling ~$149M in Multiomics and Sample Management. FY26 guidance cut to $603-621M revenue (organic -2% to +1%). Despite YTD gains of 44%, 52-week range $17.47-$41.73 highlights volatility; analysts target $35 amid fair valuation concerns.
RVTY Overview and Recent Performance
Revvity (RVTY) delivers health sciences workflows from discovery to diagnostics, with reagents, software, and imaging tech formerly under PerkinElmer. Q1 2026 revenue hit $711M (up 7%, beating estimates), adjusted EPS $1.06 (above consensus), fueled by organic growth; shares rose ~7% to ~$99. Plans to divest China immunodiagnostics aim to boost margins. Trading in 52-week $81.22-$118.30, YTD +3%, P/E 48 reflects growth premium. Recent technicals show 50-day MA crossover and positive MACD, supporting upward trend amid steady execution.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from hundreds of AI trading bots that analyze thousands of tickers across stocks, ETFs, and more, selecting only those best suited to current market conditions like volatility in semis, industrials, and life sciences. These bots employ diverse strategies—trend trading, multi-agent systems, TP/SL corridors (e.g., 3% take-profit/2% stop-loss)—on timeframes from 5min to 60min, posting annualized returns up to 169%, win rates of 51-88%, and profit factors to 4.5. For instance, semi-focused agents on NVDA/AVGO/AMD yield 72% returns at 60% win rates, while leveraged ETF bots like GGLL hit 134%. Explore these high performers to align with momentum in diagnostics and biotech tools—visit Trending AI Robots for real-time signals and copy trading options.
Head-to-Head Comparison
A, AZTA, and RVTY share life sciences exposure but diverge in models: A's broad instrumentation and services offer stability (P/E 26), contrasting RVTY's workflow tech (P/E 48, higher growth via divestitures) and AZTA's niche sample/multiomics focus amid execution risks. Recent momentum favors RVTY (Q1 beat, +7% pop) over A's steady diagnostics catalysts and AZTA's post-earnings drop. Risks include demand softness for AZTA, valuation sensitivity for RVTY, and competition for A. Sentiment tilts positive for larger caps with AI-uptrend signals, trading off AZTA's higher beta volatility.
Tickeron AI Verdict
Tickeron’s AI currently leans toward RVTY based on Q1 beat consistency, organic growth catalysts, and technical reversals like 50-day MA crossovers with positive MACD—positioning it strongly relative to peers. A follows with diagnostic approvals and undervaluation, while AZTA lags on impairments and guidance cuts. Probabilistic edge favors RVTY for trend stability in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileAZTA’s FA Score has 0 green FA rating(s), and RVTY’s FA Score reflects 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- AZTA’s FA Score: 0 green, 5 red.
- RVTY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while AZTA’s TA Score has 5 bullish TA indicator(s), and RVTY’s TA Score reflects 6 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 6 bearish.
- AZTA’s TA Score: 5 bullish, 5 bearish.
- RVTY’s TA Score: 6 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.94% price change this week, while AZTA (@Pharmaceuticals: Other) price change was -28.73% , and RVTY (@Medical Specialties) price fluctuated +7.58% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.65%. For the same industry, the average monthly price growth was +0.57%, and the average quarterly price growth was -7.69%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.67%. For the same industry, the average monthly price growth was +1.17%, and the average quarterly price growth was +21.59%.
Reported Earning Dates
A is expected to report earnings on May 27, 2026.
AZTA is expected to report earnings on Aug 11, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Medical Specialties (-0.65% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-0.67% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| A | AZTA | RVTY | |
| Capitalization | 31.9B | 808M | 11.1B |
| EBITDA | 1.82B | 36.6M | 766M |
| Gain YTD | -16.690 | -47.264 | 2.778 |
| P/E Ratio | 24.92 | 42.43 | 47.84 |
| Revenue | 7.07B | 596M | 2.86B |
| Total Cash | 1.76B | 381M | N/A |
| Total Debt | 3.35B | 55.7M | 3.4B |
A | AZTA | RVTY | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 6 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | 67 Overvalued | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 45 | 93 | 88 | |
PRICE GROWTH RATING 1..100 | 62 | 92 | 50 | |
P/E GROWTH RATING 1..100 | 57 | 86 | 33 | |
SEASONALITY SCORE 1..100 | 50 | 17 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (19) in the Biotechnology industry is somewhat better than the same rating for RVTY (52) in the Medical Specialties industry, and is somewhat better than the same rating for AZTA (67) in the Electronic Production Equipment industry. This means that A's stock grew somewhat faster than RVTY’s and somewhat faster than AZTA’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RVTY (100) in the Medical Specialties industry, and is in the same range as AZTA (100) in the Electronic Production Equipment industry. This means that A's stock grew similarly to RVTY’s and similarly to AZTA’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for RVTY (88) in the Medical Specialties industry, and is somewhat better than the same rating for AZTA (93) in the Electronic Production Equipment industry. This means that A's stock grew somewhat faster than RVTY’s and somewhat faster than AZTA’s over the last 12 months.
RVTY's Price Growth Rating (50) in the Medical Specialties industry is in the same range as A (62) in the Biotechnology industry, and is somewhat better than the same rating for AZTA (92) in the Electronic Production Equipment industry. This means that RVTY's stock grew similarly to A’s and somewhat faster than AZTA’s over the last 12 months.
RVTY's P/E Growth Rating (33) in the Medical Specialties industry is in the same range as A (57) in the Biotechnology industry, and is somewhat better than the same rating for AZTA (86) in the Electronic Production Equipment industry. This means that RVTY's stock grew similarly to A’s and somewhat faster than AZTA’s over the last 12 months.
| A | AZTA | RVTY | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 77% | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 64% | 1 day ago 72% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 56% | 1 day ago 84% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 72% | 1 day ago 72% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 80% | 1 day ago 65% |
| TrendMonth ODDS (%) | 1 day ago 65% | 1 day ago 82% | 1 day ago 61% |
| Advances ODDS (%) | 7 days ago 61% | 6 days ago 70% | 8 days ago 66% |
| Declines ODDS (%) | 3 days ago 62% | 1 day ago 82% | 15 days ago 66% |
| BollingerBands ODDS (%) | 1 day ago 59% | 1 day ago 80% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 59% | 1 day ago 79% | 1 day ago 60% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PBSE | 30.50 | 0.01 | +0.02% |
| PGIM S&P 500 Buffer 20 ETF - Sep | |||
| STOT | 47.03 | -0.01 | -0.03% |
| State Street®DoubleLine®ShrtDurTRTactETF | |||
| ISEP | 33.99 | -0.04 | -0.11% |
| Innovator Intl Dev Pwr Bffr ETF - Sept | |||
| IBCA | 25.53 | -0.09 | -0.33% |
| iShares iBonds Dec 2035 Term Corp ETF | |||
| AAXJ | 113.74 | -3.85 | -3.27% |
| iShares MSCI All Country Asia ex Jpn ETF | |||
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with MTD. These tickers have moved in lockstep 86% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then MTD could also see price increases.
AZTA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with XRAY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To AZTA | 1D Price Change % | ||
|---|---|---|---|---|
| AZTA | 100% | -2.28% | ||
| XRAY - AZTA | 63% Loosely correlated | +0.82% | ||
| IQV - AZTA | 60% Loosely correlated | +0.87% | ||
| RVTY - AZTA | 59% Loosely correlated | +0.35% | ||
| A - AZTA | 59% Loosely correlated | +1.29% | ||
| MTD - AZTA | 59% Loosely correlated | -0.56% | ||
More | ||||
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with A. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then A could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | +0.35% | ||
| A - RVTY | 73% Closely correlated | +1.29% | ||
| TMO - RVTY | 73% Closely correlated | +1.48% | ||
| IQV - RVTY | 69% Closely correlated | +0.87% | ||
| DHR - RVTY | 68% Closely correlated | -0.16% | ||
| CRL - RVTY | 66% Loosely correlated | +0.14% | ||
More | ||||